Jump to main content
Jump to site search

Issue 30, 2007
Previous Article Next Article

Coordination chemistry and biology of chelators for the treatment of iron overload disorders

Author affiliations

Abstract

Treatment of the medical condition generally referred to as iron overload through the delivery of chelators has recently received a major boost. In 2005 Novartis gained FDA approval for the drug deferasirox, which may be taken orally. Until this time most patients with Fe overload have had to endure long periods of subcutaneous infusions of the orally ineffective drug desferrioxamine (desferal) which has led to major problems with patient compliance. An effective Fe chelator must possess a number of properties for it to be able to complex Fe in vivo and be excreted intact. This Perspective will provide an overview of the current state of chelators for Fe overload; both those currently approved and those undergoing preclinical development.

Graphical abstract: Coordination chemistry and biology of chelators for the treatment of iron overload disorders

Back to tab navigation

Publication details

The article was received on 29 May 2007, accepted on 18 Jun 2007 and first published on 05 Jul 2007


Article type: Perspective
DOI: 10.1039/B708133B
Citation: Dalton Trans., 2007,0, 3214-3220
  •   Request permissions

    Coordination chemistry and biology of chelators for the treatment of iron overload disorders

    P. V. Bernhardt, Dalton Trans., 2007, 0, 3214
    DOI: 10.1039/B708133B

Search articles by author

Spotlight

Advertisements